PGR and breast carcinoma: Lonaprisan (also called BAY 86-5044), which is a potent synthetic selective antagonist of the progesterone receptor and a potential treatment of breast cancer, has been shown to increase myelinated axon numbers and to improve poor motor phenotypes [31].